Drugs / RG-7741
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01564251 | Mar 2012 → Jan 2018 | lymphoma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG-7741 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545199 ↗ |
| Known as | GDC-0575 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01564251 ↗ |
| Action | Inhibit | “GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor” PMID 29788155 ↗ May 20181“Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL3545199 ↗ |
| Modality | Small molecule | “GDC-0575 is a highly-selective oral small-molecule Chk1 inhibitor” PMID 29788155 ↗ May 2018 |
| Route | Oral | “GDC-0575 administered orally” NCT01564251 ↗ |
| Target | CHEK1 | “Serine/threonine-protein kinase Chk1 inhibitor” CHEMBL3545199 ↗ |